Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 5;9(9):1881.
doi: 10.3390/microorganisms9091881.

Cholesterol-to-Coprostanol Conversion by the Gut Microbiota: What We Know, Suspect, and Ignore

Affiliations
Review

Cholesterol-to-Coprostanol Conversion by the Gut Microbiota: What We Know, Suspect, and Ignore

Catherine Juste et al. Microorganisms. .

Abstract

Every day, up to 1 g of cholesterol, composed of the unabsorbed dietary cholesterol, the biliary cholesterol secretion, and cholesterol of cells sloughed from the intestinal epithelium, enters the colon. All cholesterol arriving in the large intestine can be metabolized by the colonic bacteria. Cholesterol is mainly converted into coprostanol, a non-absorbable sterol that is excreted in the feces. Interestingly, cholesterol-to-coprostanol conversion in human populations is variable, with a majority of high converters and a minority of low or inefficient converters. Two major pathways have been proposed, one involving the direct stereospecific reduction of the Δ5 double bond direct while the indirect pathway involves the intermediate formation of 4-cholelesten-3-one and coprostanone. Despite the fact that intestinal cholesterol conversion was discovered more than a century ago, only a few cholesterol-to-coprostanol-converting bacterial strains have been isolated and characterized. Moreover, the responsible genes were mainly unknown until recently. Interestingly, cholesterol-to-coprostanol conversion is highly regulated by the diet. Finally, this gut bacterial metabolism has been linked to health and disease, and recent evidence suggests it could contribute to lower blood cholesterol and cardiovascular risks.

Keywords: bile acids; cholesterol; coprostanol; feces; gut microbiome; intestine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Estimation of daily cholesterol input and output in the healthy adult.
Figure 2
Figure 2
Planar representation of cholesterol (A) and coprostanol (B).
Figure 3
Figure 3
Direct and indirect pathways for the conversion of cholesterol to coprostanol by the gut microbiota. The indirect pathway (II, large grey arrow) is by far the most probable as evidenced by identification of the intermediates in crude feces and cultures of pure active strains. The direct pathway (I) cannot be excluded but never received any proof of evidence. Note that isomerization of cholesterol to allocholesterol and then reduction of allocholesterol to coprostanol (pathway III) are chemical reactions that, until proved otherwise, do not proceed in any organism. * Intermediate seen in GC-MS analyses of feces or pure active cultures. Micro-organisms and enzymes involved in the considered reaction are mentioned; black and grey characters correspond to confirmed and uncertain knowledge, respectively. A micro-organism is confirmed if it has been shown to process to the reaction in pure culture. An enzyme is confirmed if it has been purified and characterized in at least one gut micro-organism.

References

    1. Barquera S., Pedroza-Tobías A., Medina C., Hernández-Barrera L., Bibbins-Domingo K., Lozano R., Moran A.E. Global overview of the epidemiology of atherosclerotic cardiovascular disease. Arch. Med. Res. 2015;46:328–338. doi: 10.1016/j.arcmed.2015.06.006. - DOI - PubMed
    1. Catapano A.L., Farnier M., Foody J.M., Toth P.P., Tomassini J.E., Brudi P., Tershakovec A.M. Combination therapy in dyslipidemia: Where are we now? Atherosclerosis. 2014;237:319–335. doi: 10.1016/j.atherosclerosis.2014.09.026. - DOI - PubMed
    1. Beitz D.C. Administration of Cholesterol Reductase to Humans. No. 5,436,004. Patent Application. 1995 July 25;
    1. Li L., Batt S.M., Wannemuehler M., Dispirito A., Beitz D.C. Effect of feeding of a cholesterol-reducing bacterium, Eubacterium coprostanoligenes, to germ-free mice. Lab. Anim. Sci. 1998;48:253–255. - PubMed
    1. Beitz D.C., Young J.W., Dehal S.S. Method of Converting Cholesterol in Food to Coprostanol. No. 4,921,710. Patent Application. 1990 May 1;

LinkOut - more resources